July 9, 2016 09:13 AM EDTUpdated July 10, 02:21 PM
Bioregnum
Pharma
Opinion

Why we need to low­er U.S. reg­u­la­to­ry bar­ri­ers around biosim­i­lar ap­provals now

The FDA’s in­ter­nal re­view on Am­gen’s biosim­i­lar of Hu­mi­ra reads like a prod­uct en­dorse­ment. Post­ed on Fri­day, the agency in­sid­ers es­sen­tial­ly said: Let’s give it …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers 

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

A service from the Financial Times